SIHUAN PHARM (00460.HK) announced its annual results, with sales revenue from the medical beauty Business increasing by approximately 65.4%.

On March 17, Glonghui announced that SIHUAN PHARM (00460.HK) achieved total revenue of approximately RMB 1901.1 million for the fiscal year ending December 31, 2024, reflecting an increase of about 2.2% year-on-year. Revenue from the medical beauty Business was approximately RMB 744.2 million, up about 65.4% year-on-year, mainly due to the high market recognition of products during the year, which significantly boosted medical beauty sales revenue, alongside new income generated from product sales. Revenue from Innovative Drugs and Other Pharmaceuticals was approximately RMB 57.6 million, up about 388.1% year-on-year.

Gelonghui FinanceMar 28 00:30 ET

Express News | Sihuan Pharmaceutical Holdings Group FY Pretax Profit RMB -428.3 Million

ReutersMar 28 00:01 ET

Express News | Sihuan Pharmaceutical Holdings Group FY Gross Margin 65.3%

ReutersMar 28 00:01 ET

Express News | Sihuan Pharmaceutical Holdings Group FY Gross Profit RMB 1,241.7 Million

ReutersMar 28 00:01 ET

Express News | Sihuan Pharmaceutical Holdings Group FY Revenue RMB 1,901.1 Million

ReutersMar 28 00:01 ET

SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024

HKEXMar 28 00:00 ET · Announcements